Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

For patients with metastatic pancreatic cancer that are not eligible for surgery, signal-targeted therapies have so far failed to significantly improve survival. These therapeutic options have been tested in phase II/III clinical trials mostly in combination with the reference treatment gemcitabine....

Descripción completa

Detalles Bibliográficos
Autores principales: Cintas, Célia, Douché, Thibaut, Therville, Nicole, Arcucci, Silvia, Ramos-Delgado, Fernanda, Basset, Céline, Thibault, Benoît, Guillermet-Guibert, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025626/
https://www.ncbi.nlm.nih.gov/pubmed/29865155
http://dx.doi.org/10.3390/cancers10060174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025626/
https://www.ncbi.nlm.nih.gov/pubmed/29865155
http://dx.doi.org/10.3390/cancers10060174

Ejemplares similares